JP2012508172A5 - - Google Patents

Download PDF

Info

Publication number
JP2012508172A5
JP2012508172A5 JP2011534887A JP2011534887A JP2012508172A5 JP 2012508172 A5 JP2012508172 A5 JP 2012508172A5 JP 2011534887 A JP2011534887 A JP 2011534887A JP 2011534887 A JP2011534887 A JP 2011534887A JP 2012508172 A5 JP2012508172 A5 JP 2012508172A5
Authority
JP
Japan
Prior art keywords
factor according
coagulation factor
starch
amino acid
coagulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011534887A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012508172A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2009/063151 external-priority patent/WO2010062768A1/en
Publication of JP2012508172A publication Critical patent/JP2012508172A/ja
Publication of JP2012508172A5 publication Critical patent/JP2012508172A5/ja
Pending legal-status Critical Current

Links

JP2011534887A 2008-11-03 2009-11-03 血友病の治療方法 Pending JP2012508172A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11080908P 2008-11-03 2008-11-03
US61/110,809 2008-11-03
PCT/US2009/063151 WO2010062768A1 (en) 2008-11-03 2009-11-03 Method for the treatment of hemophilia

Publications (2)

Publication Number Publication Date
JP2012508172A JP2012508172A (ja) 2012-04-05
JP2012508172A5 true JP2012508172A5 (enExample) 2012-12-20

Family

ID=42225997

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011534887A Pending JP2012508172A (ja) 2008-11-03 2009-11-03 血友病の治療方法

Country Status (7)

Country Link
US (1) US20120027743A1 (enExample)
EP (1) EP2352515A4 (enExample)
JP (1) JP2012508172A (enExample)
KR (1) KR20110093775A (enExample)
CN (1) CN102202684A (enExample)
CA (1) CA2740793A1 (enExample)
WO (1) WO2010062768A1 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2101821T3 (da) 2006-12-15 2014-10-06 Baxter Healthcare Sa Faktor VIIA-(poly)sialinsyre-konjugat med forlænget halveringstid in vivo
EP2244814B1 (en) * 2007-12-28 2021-06-02 Takeda Pharmaceutical Company Limited Recombinant vwf formulations
US11197916B2 (en) 2007-12-28 2021-12-14 Takeda Pharmaceutical Company Limited Lyophilized recombinant VWF formulations
EP2349314B1 (en) 2008-10-21 2013-02-27 Baxter International Inc. Lyophilized recombinant vwf formulations
DK3178835T3 (da) 2009-02-03 2019-06-24 Amunix Pharmaceuticals Inc Forlængede rekombinante polypeptider og sammensætninger omfattende samme
RU2744370C2 (ru) 2009-07-27 2021-03-05 Баксалта Инкорпорейтед Конъюгаты белков свертывания крови
EP3081233B1 (en) 2009-07-27 2020-12-23 Baxalta GmbH Glycopolysialylation of proteins other than blood coagulation proteins
BR112012001814A8 (pt) 2009-07-27 2018-02-06 Baxalta GmbH Conjugados de proteína de coagulação sanguínea
US8642737B2 (en) 2010-07-26 2014-02-04 Baxter International Inc. Nucleophilic catalysts for oxime linkage
US8809501B2 (en) 2009-07-27 2014-08-19 Baxter International Inc. Nucleophilic catalysts for oxime linkage
CA2771999A1 (en) 2009-08-24 2011-03-10 Amunix Operating Inc. Coagulation factor vii compositions and methods of making and using same
GB201007356D0 (en) 2010-04-30 2010-06-16 Leverton Licence Holdings Ltd Conjugated factor VIIa
ES2800983T3 (es) 2010-12-22 2021-01-07 Baxalta GmbH Materiales y métodos para conjugar un derivado de ácido graso soluble en agua con una proteína
WO2013123457A1 (en) 2012-02-15 2013-08-22 Biogen Idec Ma Inc. Recombinant factor viii proteins
CN111548418A (zh) 2012-02-15 2020-08-18 比奥贝拉蒂治疗公司 因子viii组合物及其制备和使用方法
US20150080309A1 (en) 2012-04-24 2015-03-19 Nova Nordisk A/S Compounds Suitable for Treatment of Haemophilia
US20150045303A1 (en) 2012-04-24 2015-02-12 Novo Nordisk A/S Pharmaceutical Composition Suitable for Treatment of Haemophilia
US10548953B2 (en) 2013-08-14 2020-02-04 Bioverativ Therapeutics Inc. Factor VIII-XTEN fusions and uses thereof
EA201691111A1 (ru) 2014-01-10 2017-01-30 Байоджен Ма Инк. Химерные белки фактора viii и их применение
UA126016C2 (uk) 2015-08-03 2022-08-03 Біовератів Терапеутікс Інк. Злитий білок фактора іх
KR20190090827A (ko) 2016-12-02 2019-08-02 바이오버라티브 테라퓨틱스 인크. 키메라 응고 인자를 사용해 혈우병성 관절증을 치료하는 방법
KR102914074B1 (ko) 2018-05-18 2026-01-16 바이오버라티브 테라퓨틱스 인크. A형 혈우병의 치료 방법

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5766897A (en) * 1990-06-21 1998-06-16 Incyte Pharmaceuticals, Inc. Cysteine-pegylated proteins
FR2686899B1 (fr) * 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
IL113010A0 (en) * 1994-03-31 1995-10-31 Pharmacia Ab Pharmaceutical formulation comprising factor VIII or factor ix with an activity of at least 200 IU/ml and an enhancer for improved subcutaneous intramuscular or intradermal administration
SE9503380D0 (sv) * 1995-09-29 1995-09-29 Pharmacia Ab Protein derivatives
US8465468B1 (en) * 2000-06-29 2013-06-18 Becton, Dickinson And Company Intradermal delivery of substances
EP1596887B1 (en) * 2003-02-26 2022-03-23 Nektar Therapeutics Polymer-factor viii moiety conjugates
DK2371856T3 (en) * 2004-11-12 2022-08-08 Bayer Healthcare Llc Site-directed modifikation af FVIII
US20080227691A1 (en) * 2005-04-01 2008-09-18 Novo Nordisk Health Care Ag Blood Coagulation FVIII Analogues
JP5558106B2 (ja) * 2007-01-03 2014-07-23 ノボ ノルディスク ヘルス ケア アーゲー 凝固第vii因子関連ポリペプチドの皮下投与
WO2008119815A1 (en) * 2007-04-02 2008-10-09 Novo Nordisk A/S Subcutaneous administration of coagulation factor ix

Similar Documents

Publication Publication Date Title
JP2013519636A5 (enExample)
Kadajji et al. Water soluble polymers for pharmaceutical applications
Nita et al. New trends in bio-based aerogels
JP2018040002A5 (enExample)
Chan et al. Pectin as a rheology modifier: Origin, structure, commercial production and rheology
Moscovici Present and future medical applications of microbial exopolysaccharides
JP2018535704A5 (enExample)
JP2008516735A5 (enExample)
JP2016073641A5 (enExample)
JP2013519697A5 (enExample)
Dumitriu Polysaccharides as biomaterials
Hardy et al. β‑Cyclodextrin-Functionalized Chitosan/Alginate Compact Polyelectrolyte Complexes (CoPECs) as Functional Biomaterials with Anti-Inflammatory Properties
JP2012506904A5 (enExample)
JP2015516240A5 (enExample)
Das et al. A polysaccharide-based pH-sensitive hybrid hydrogel as a sustained release matrix for antimicrobial drugs
Wahab et al. Polysaccharides as composite biomaterials
JP2006522829A5 (enExample)
Al-Roujayee et al. Alginate-based systems: advancements in drug delivery and wound healing
Youn et al. Tissue adhesives based on chitosan for biomedical applications
Sirisha et al. Polysaccharide-based nanoparticles as drug delivery systems
Fatima et al. Diversity of rationally modified polysaccharides for pharmaceutical applications
JP2011513393A5 (enExample)
Sousa et al. Marine-origin polysaccharides and their chemically modified derivatives as sources of advanced biofunctional materials for biomedical applications
Neamtu et al. Nanogels containing polysaccharides for bioapplications
Abdel-Rahman et al. Hyaluronan/Zinc oxide nanocomposite-based membrane: preparation, characterization, and in vitro and in vivo evaluation